Načítá se...
Autoimmune Encephalitis After Treatment of Hodgkin’s Lymphoma with the Immune Checkpoint Inhibitor Nivolumab
In recent years, by the usage of new immune therapeutic agents for cancer treatment, the neurologic adverse events began to be seen more frequently. Nivolumab, one of the immune checkpoint inhibitor, is a human IgG4 antibody that blocks programmed cell death protein 1 and is approved against metasta...
Uloženo v:
| Vydáno v: | Noro Psikiyatr Ars |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Noro-Psikiyatri Arsivi
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8214751/ https://ncbi.nlm.nih.gov/pubmed/34188600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.29399/npa.23353 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|